Pharmacologic reduction of factor XIII activity and fibrinogenemia in patients with peripheral arterial occlusive disease

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 6, 1998, Pages 389-394

  Pola, Paolo ^a   Dal Lago, Antonio ^a   Flore, Roberto ^a   De Martini, Demetrio ^a   Gaetani, Eleonora ^a   Gasbarrini, Antonio ^a   Gerardino, Laura ^a   Santoliquido, Angelo ^a   Tondi, Paolo ^a   Serricchio, Michele ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Defibrotide; Factor XIII; Hyperfibrinogenemia; Peripheral arterial occlusive disease

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; DEFIBROTIDE; FIBRIN MONOMER; FIBRINOGEN; PLACEBO; SODIUM CHLORIDE;

ADULT; AGED; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE AGGREGATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE AGGREGATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 7144235819     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85041-8     Document Type: Article

References (18)

1. Tamaki T, Aoki N. Crosslinking of alfa-2 plasmin inhibitor and fibronectin to fibrin by fibrin stabilizing factor. Biochem Biophys Acta. 1981;661:280-286.
2. Doolittle RF. Fibrinogen and fibrin. Sci Am. 1981;245:92-101.
3. Henschen A. Fibrinogen-Coagulation factor I. Biochemical aspects. Haemostaseologie. 1981;1:30-40.
4. Sane DC, Moser TL, Pippen AMM, et al. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun. 1988;157:115-120.
5. Baer U, Bauknecht J, Stangl T, Haering R. Reduction of the wound healing time during pre or postsurgical quantitative substitution of FXIII. Zentralbl Chir. 1980;105:642.
6. Folsom AR. Epidemiology of fibrinogen. Eur Heart J. 1995;16(Suppl A):21-24.
7. Cucuianu M, Knauer O, Roman S. Alfa-2 antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states. Thromb Haemost. 1991;66:586-591.
8. Herren T, Stricker H, Haeberli A, et al. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation. 1994;90:2679-2686.
9. Smith FB, Lowe GD, Fowkes FG, et al. Smoking, haemostatic factors and lipid peroxides in a population case-control study of peripheral arterial disease. Atherosclerosis. 1993; 102:155-162.
10. Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Variations of haemostasis parameters with special reference to fibrin stabilization FXIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res. 1988;51:575-581.
11. Cortellaro M, Cofrancesco E, Boschetti C, et al. Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. The PLAT group. Thromb Haemost. 1994;72:292-296.
12. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J. 1995;16(Suppl A):11-15.
13. Tesi M, Spina T. Endothelium and thrombophilia. G Ital Angiol. 1995;XV:9-14.
14. Pola P, Savi L. Factor XIII inhibition as a prophylactic and therapeutic perspective in atherosclerosis. Minerva Cardioangiol. 1977;25:643-646.
15. Pola P, Tondi P, Favuzzi A, et al. Treatment of retinal vein thrombosis with defibrotide. Curr Ther Res. 1993;53:340-346.
16. Pola P, Tondi P, De Martini D, et al. Variations of fibrinogen, tPA and PAI-1 after IV administration of defibrotide. G Ital Angiol. 1994;XIV:14-18.
17. Fickensher K, Aab A, Stueber W. A photometric assay for blood coagulation FXIII. Thromb Haemost. 1991;65:535-540.
18. Wagner B, Seyfert UT, Grosse M, et al. Determination of Factor XIII activity by a new photometric assay in plasma and platelets of healthy blood donors. Thromb Res. 1994; 74:169-174.